+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Disorders of Protein Synthesis. Advances in Protein Chemistry and Structural Biology Volume 132

  • Book

  • September 2022
  • Elsevier Science and Technology
  • ID: 5658497

Disorders of Protein Synthesis, Volume 132 in the Advances in Protein Chemistry and Structural Biology series, highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Contributors in this volume include:
Alessio Branchini
Fabio Di Domenico
Baris Akinci
Asim Kanti Duttaroy
Qiaozhu Su
Maria I. Vaccaro
Nicola Luigi Bragazzi
Chandrabose Selvaraj
Nicola Luigi Bragazzi
C. George Priya Doss
C. George Priya Doss
V�ctor Garc�a-Gonz�lez
Mojgan Rastegar

Authors

Rossen Donev Head of Research, MicroPharm Limited, UK. Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.